Free Access
Volume 24, Number 4, Juillet 2015
Quid des patients spécifiques ?
Page(s) 424 - 432
Section Mise Au Point / Update
Published online 29 May 2015
  • Louis DN, Ohgaki H, Wiestler OD, et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (Berl) 114:97–109 [Google Scholar]
  • Ostrom QT, Gittleman H, Farah P, et al (2013) CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15(Suppl 2):ii1–56 [CrossRef] [PubMed] [Google Scholar]
  • Ricard D, Idbaih A, Ducray F, et al (2012) Primary brain tumours in adults. Lancet 379:1984–96 [CrossRef] [PubMed] [Google Scholar]
  • No authors listed] (1999) Guidelines for intensive care unit admission, discharge, and triage. Task Force of the American College of Critical Care Medicine, Society of Critical Care Medicine. Crit Care Med 27:633–8 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Mason WP, van den Bent MJ, et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–96 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Hegi ME, Mason WP, et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 10:459–66 [CrossRef] [PubMed] [Google Scholar]
  • Hegi ME, Diserens AC, Gorlia T, et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997–1003 [CrossRef] [PubMed] [Google Scholar]
  • van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al (2013) MGMT-STP27 methylation status as predictive marker for response to PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clin Cancer Res 19:5513–22 [CrossRef] [PubMed] [Google Scholar]
  • Cairncross G, Wang M, Shaw E, et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol. 31:337–43 [CrossRef] [PubMed] [Google Scholar]
  • Kostakou E, Rovina N, Kyriakopoulou M, et al (2014) Critically ill cancer patient in intensive care unit: Issues that arise. J Crit Care S0883-9441:00145–2 [Google Scholar]
  • Azoulay E, Soares M, Darmon M, et al (2011) Intensive care of the cancer patient: recent achievements and remaining challenges. Ann Intensive Care 1:5 [CrossRef] [PubMed] [Google Scholar]
  • Peigne V, Rusinová K, Karlin L, et al (2009) Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med 35:512–8 [CrossRef] [PubMed] [Google Scholar]
  • Legriel S, Marijon H, Darmon M, et al (2010) Central neurological complications in critically ill patients with malignancies. Intensive Care Med 36:232–40 [CrossRef] [PubMed] [Google Scholar]
  • Johnson DR, Brown PD, Galanis E, Hammack JE (2012) Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. J Neurooncol 108:187–93 [CrossRef] [PubMed] [Google Scholar]
  • Bautista F, Paci A, Minard-Colin V, et al (2014) Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas. Pediatr Blood Cancer 61:1101–3 [CrossRef] [PubMed] [Google Scholar]
  • Skrypek M, Foreman N, Guillaume D, Moertel C (2014) Pilomyxoid astrocytoma treated successfully with vemurafenib. Pediatr Blood Cancer 61:2099–100 [CrossRef] [PubMed] [Google Scholar]
  • Pignatti F, van den Bent M, Curran D, et al (2002) Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20:2076–84 [CrossRef] [PubMed] [Google Scholar]
  • Soffietti R, Baumert BG, Bello L, et al (2010) Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol 17:1124–33 [CrossRef] [PubMed] [Google Scholar]
  • Daniels TB, Brown PD, Felten SJ, et al (2011) Validation of EORTC prognostic factors for adults with low-grade glioma: a report using intergroup 86-72-51. Int J Radiat Oncol Biol Phys. 81:218–24 [CrossRef] [PubMed] [Google Scholar]
  • Mandonnet E, Delattre JY, Tanguy ML, et al (2003) Continuous growth of mean tumor diameter in a subset of grade II gliomas. Ann Neurol. 2003 53:524–8 [Google Scholar]
  • Rigau V, Zouaoui S, Mathieu-Daudé H, et al (2011) French brain tumor database: 5-year histological results on 25 756 cases. Brain Pathol 21:633–44 [CrossRef] [PubMed] [Google Scholar]
  • Houillier C, Wang X, Kaloshi G, et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75:1560–6 [CrossRef] [PubMed] [Google Scholar]
  • Everhard S, Tost J, El Abdalaoui H, et al (2009) Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas. Neuro Oncol 11:348–56 [CrossRef] [PubMed] [Google Scholar]
  • Gorlia T, Delattre JY, Brandes AA, et al (2013) New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. Eur J Cancer 49:3477–85 [CrossRef] [PubMed] [Google Scholar]
  • Panageas KS, Reiner AS, Iwamoto FM, et al (2014) Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol 16:1541–6 [CrossRef] [PubMed] [Google Scholar]
  • Stupp R, Reni M, Gatta G, et al (2007) Anaplastic astrocytoma in adults. Crit Rev Oncol Hematol 63:72–80 [CrossRef] [PubMed] [Google Scholar]
  • van den Bent MJ, Brandes AA, Taphoorn MJ, et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–50 [CrossRef] [PubMed] [Google Scholar]
  • Cairncross JG, Wang M, Jenkins RB, et al (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783–90 [CrossRef] [PubMed] [Google Scholar]
  • Li J, Wang M, Won M, et al (2011) Validation and simplification of the Radiation Therapy Oncology Group recursive partitioning analysis classification for glioblastoma. Int J Radiat Oncol Biol Phys 81:623–30 [CrossRef] [PubMed] [Google Scholar]
  • Esteller M, Garcia-Foncillas J, Andion E, et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350–4 [CrossRef] [PubMed] [Google Scholar]
  • Tabouret E, Chinot O, Sanson M, et al (2014) Predictive biomarkers investigated in glioblastoma. Expert Rev Mol Diagn 14:883–93 [CrossRef] [PubMed] [Google Scholar]
  • Korfel A, Schlegel U (2013) Diagnosis and treatment of primary CNS lymphoma. Nat Rev Neurol 9:317–27 [CrossRef] [PubMed] [Google Scholar]
  • Sierra del Rio M, Rousseau A, Soussain C, et al (2009) CNS lymphoma in immunocompetent patients. Oncologist 14:526–39 [CrossRef] [PubMed] [Google Scholar]
  • Abrey LE, Ben-Porat L, Panageas KS, et al (2006) Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 24:5711–5 [CrossRef] [PubMed] [Google Scholar]
  • Taal W, Oosterkamp HM, Walenkamp AM, et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–53 [CrossRef] [PubMed] [Google Scholar]
  • Gilbert MR, Dignam JJ, Armstrong TS, et al (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708 [CrossRef] [PubMed] [Google Scholar]
  • Chinot OL, Wick W, Mason W, et al (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–22 [CrossRef] [PubMed] [Google Scholar]
  • Taccone FS, Artigas AA, Sprung CL, et al (2009) Characteristics and outcomes of cancer patients in European ICUs. Crit Care 13:R15 [CrossRef] [PubMed] [Google Scholar]
  • Soares M, Salluh JI, Torres VB, et al (2005) Short- and long-term outcomes of critically ill patients with cancer and prolonged ICU length of stay. Chest 134:520–6 [CrossRef] [Google Scholar]
  • Cavaliere R, Farace E, Schiff D (2006) Clinical implications of status epilepticus in patients with neoplasms. Arch Neurol 63:1746–9 [CrossRef] [PubMed] [Google Scholar]
  • Ferlisi M, Shorvon S (2012) The outcome of therapies in refractory and super-refractory convulsive status epilepticus and recommendations for therapy. Brain J Neurol 135:2314–28 [CrossRef] [Google Scholar]
  • Kennedy J, Schuele SU (2013) Long-term monitoring of brain tumors: when is it necessary? Epilepsia 54 Suppl 9:50–5 [CrossRef] [Google Scholar]
  • Marcuse LV, Lancman G, Demopoulos A, Fields M (2014) Nonconvulsive status epilepticus in patients with brain tumors. Seizure 23:542–7 [CrossRef] [PubMed] [Google Scholar]
  • Schmiegelow K. (2009) Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 146:489–503 [CrossRef] [PubMed] [Google Scholar]
  • Roch A, Wiramus S, Pauly V, et al (2011) Long-term outcome in medical patients aged 80 or over following admission to an intensive care unit. Crit Care 15:R36 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Azoulay E. (2009) Critical care management of cancer patients: cause for optimism and need for objectivity. Curr Opin Oncol 21:318–26 [CrossRef] [PubMed] [Google Scholar]
  • Boussat S, El’rini T, Dubiez A, et al (2000) Predictive factors of death in primary lung cancer patients on admission to the intensive care unit. Intensive Care Med 26:1811–6 [CrossRef] [PubMed] [Google Scholar]
  • Kopterides P, Liberopoulos P, Ilias I, et al (2011) General prognostic scores in outcome prediction for cancer patients admitted to the intensive care unit. Am J Crit Care 20:56–66 [CrossRef] [PubMed] [Google Scholar]
  • Aygencel G, Turkoglu M, Turkoz Sucak G, Benekli M. (2014) Prognostic factors in critically ill cancer patients admitted to the intensive care unit. J Crit Care 29:618–26 [CrossRef] [PubMed] [Google Scholar]
  • Darmon M, Thiery G, Ciroldi M, et al (2005) Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 33:2488–93 [CrossRef] [PubMed] [Google Scholar]
  • Thiéry G, Azoulay E, Darmon M, et al (2005) Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study. J Clin Oncol 23:4406–13 [CrossRef] [PubMed] [Google Scholar]
  • Lecuyer L, Chevret S, Thiery G, et al (2007) The ICU trial: a new admission policy for cancer patients requiring mechanical ventilation. Crit Care Med 2007 35:808–14 [CrossRef] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.